Der Gynäkologe

, Volume 39, Issue 12, pp 975–980 | Cite as

Adipositas und Krebs

Zum Thema
  • 179 Downloads

Zusammenfassung

Die Prävalenz der Adipositas nimmt in alarmierendem Ausmaß zu. Gesundheitliche wie ökonomische Konsequenzen sind bedeutsam, da Adipositas mit zahlreichen Erkrankungen assoziiert ist. Umfangreiche prospektive Studien zeigen, dass Adipositas auch mit mehreren Krebsarten signifikant assoziiert ist. Die IARC der WHO hält die Beweise hinsichtlich des kausalen Zusammenhanges von Übergewicht und Karzinomen des Kolons, der Mamma (postmenopausal), des Endometriums, der Niere (Nierenzellkarzinom) und des Ösophagus (Adenokarzinom) für ausreichend. Zu den potenziellen pathogenetischen Mechanismen gehören u. a. gesteigerte Insulinresistenz, chronische Hyperinsulinämie und die erhöhte Bioverfügbarkeit von Steroidhormonen. Zudem konnte gezeigt werden, dass Adipozytokine in gewissem Maß am Prozess der Karzinogenese beteiligt sind. Am überzeugendsten hat die Women’s Intervention Nutrition Study zeigen können, dass Lebensstiländerungen das Risiko für ein erneutes Auftreten von Brustkrebs sogar vermindern können.

Schlüsselwörter

Adipositas Tumorrisiko Metabolisches Syndrom Lebensstilfaktoren 

Obesity and cancer

Abstract

The prevalence of obesity is growing alarmingly and the consequences for health and economy are important since obesity is associated with many diseases. Large prospective studies have shown a significant association of obesity with several cancers and the International Agency for Research on Cancer of the WHO has classified the evidence of a causal link as “sufficient” for cancers of the colon, female breast (postmenopause), endometrium, kidney (renal cell) and esophagus (adenocarcinoma). The potential mechanisms vary with cancer site and include insulin resistance and resultant chronic hyperinsulinemia, as well as increased bioavailability of steroid hormones. In addition, adipocytokines, a group of adipose tissue-derived hormones, were shown to participate to some extent in the process of carcinogenesis. The recent release of the Women’s Intervention Nutrition Study has demonstrated most convincingly that lifestyle modifications can even decrease the risk of breast cancer recurrence.

Keywords

Obesity Tumor risk Metabolic syndrome Lifestyle factors 

Notes

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Literatur

  1. 1.
    Ballard-Barbash R, Swanson CA (1996) Body weight: estimation of risk for breast and endometrial cancer. Am J Clin Nutr 63 [Suppl 3]: 437–441Google Scholar
  2. 2.
    Bastarrachea J, Hortobagyi GN, Smith TL et al. (1994) Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med 120: 18PubMedGoogle Scholar
  3. 3.
    Benecke A, Vogel H (2005) Übergewicht und Adipositas. Gesundheitsberichterstattung des Bundes, 16: 7–28. Robert-Koch-Institut, Berlin, http://www.rki.de
  4. 4.
    Bergmann KE, Mensink GBM (1999) Körpermaße und Übergewicht. Gesundheitswesen 61, Sonderheft 2: 115–120Google Scholar
  5. 5.
    Bergstrom A, Pisani P, Tenet V et al. (2001) Overweight as an avoidable cause of cancer in Europe. Int J Cancer 91: 421–430CrossRefPubMedGoogle Scholar
  6. 6.
    Blitzer PH, Blitzer EC, Rimm AA (1976) Association between teenage obesity and cancer in 56,111 women: all cancers and endometrial carcinoma. Prev Med 5: 20CrossRefPubMedGoogle Scholar
  7. 7.
    Bosello O, Zamboni M (2000) Visceral obesity and metabolic syndrome. Obes Rev 1: 47–56CrossRefPubMedGoogle Scholar
  8. 8.
    Calle EE, Thun MJ, Petrelli JM et al. (1999) Body-mass-index and mortality in a prospective cohort of US adults. N Engl J Med 341: 1097–1105PubMedGoogle Scholar
  9. 9.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 348: 1625–1638CrossRefPubMedGoogle Scholar
  10. 10.
    Calle EE, Thun MJ (2004) Obesity and cancer. Oncogene 23: 6365–6378CrossRefPubMedGoogle Scholar
  11. 11.
    Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4: 579–591CrossRefPubMedGoogle Scholar
  12. 12.
    Chlebowski RT, Aiello E, McTiernan A (2002) Weight loss in breast cancer management. J Clin Oncol 20: 1128–1143Google Scholar
  13. 13.
    Chlebowski RT, Blackburn G, Elashoff R et al. (2005) Dietary fat reduction in postmenopausal women with primary breast cancer: Phase III Women’s Intervention Nutrition Study (WINS). J Clin Oncol 23: 3s (suppl; abstr 10)Google Scholar
  14. 14.
    Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 350: 1047–1059CrossRefPubMedGoogle Scholar
  15. 15.
    Doll R, Peto R (1981) The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 66: 1191–1308PubMedGoogle Scholar
  16. 16.
    Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365: 1415–1428CrossRefPubMedGoogle Scholar
  17. 17.
    Ehrmann DA (2005) Polycystic ovary syndrome. N Engl J Med 352: 1223–1236CrossRefPubMedGoogle Scholar
  18. 18.
    Eifel PJ, Jhingran A, Bodurka DC et al. (2002) Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer. J Clin Oncol 20: 3651Google Scholar
  19. 19.
    Emons G, Fleckenstein G, Hinney B et al. (2000) Hormonal interactions in endometrial cancer. Endocr Relat Cancer 7: 227–242CrossRefPubMedGoogle Scholar
  20. 20.
    Feigelson HS, Jonas CR, Teras LR et al. (2004) Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomark Prev 13: 220–224CrossRefGoogle Scholar
  21. 21.
    Galanis DJ et al. (1998) Anthropometric predictors of breast cancer incidence and survival in a multi-ethnic cohort of female residents of Hawaii, United States. Cancer Causes Control 9: 217–224CrossRefPubMedGoogle Scholar
  22. 22.
    Garofalo C, Surmacz E (2006) Leptin and cancer. J Cell Physiol 207: 12–22CrossRefPubMedGoogle Scholar
  23. 23.
    Greenwald P, Weed DL (1995) Cancer prevention and control, cancer causes and control. Harvard report on cancer prevention. Causes of human cancer, vol 1. Marcel Dekker, New York, pp 55–58Google Scholar
  24. 24.
    Griffin ME, Marcucci MJ, Cline GW et al. (1999) Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48: 1270–1274PubMedGoogle Scholar
  25. 25.
    Goodwin P (2006) Energy balance and cancer prognosis: Breast cancer. In: McTiernan A (ed) Cancer prevention and management through exercise and weight control. Boca Raton, Fl, Taylor and Francis Group, pp 405–435Google Scholar
  26. 26.
    Hankinson SE, Willett WC, Colditz GA et al. (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393–1396CrossRefPubMedGoogle Scholar
  27. 27.
    Hankinson SE, Willett WC, Manson JE et al. (1998) Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 90: 1292–1299CrossRefPubMedGoogle Scholar
  28. 28.
    Higginson J, Muir CS (1979) Environmental carcinogenesis: misconceptions and limitations to cancer control. J Natl Cancer Inst 63: 1291–1298PubMedGoogle Scholar
  29. 29.
    Holmes M, Chen W, Feskanich D et al. (2005) Physical activity and survival after breast cancer diagnosis. JAMA 293: 2479–2486CrossRefPubMedGoogle Scholar
  30. 30.
    Hotamisligil GS (1999) The role of TNF-alpha and TNF-receptors in obesity and insulin resistance. J Intern Med 245: 621–625CrossRefPubMedGoogle Scholar
  31. 31.
    Housa D, Housova J, Vernerovka Z, Haluzik M (2006) Adipocytokines and cancer. Physiol Res 55: 233–244PubMedGoogle Scholar
  32. 32.
    Huang Z et al. (1997) Dual effects of weight and weight gain on breast cancer risk. JAMA 278: 1407–1411CrossRefPubMedGoogle Scholar
  33. 33.
    Hunter DJ, Willett WC (1993) Diet, body size, and breast cancer. Epidemiol Rev 15: 110–132PubMedGoogle Scholar
  34. 34.
    IACR (2002) Weight control and physical activity. International Agency for Research on Cancer, vol 6. Lyon, FranceGoogle Scholar
  35. 35.
    Jee SH, Kim HJ, Lee J (2005) Obesity, insulin resistance and cancer risk. Yonsei Med J 46: 449–455PubMedGoogle Scholar
  36. 36.
    Kaaks R (1996) Nutrition, hormones, and breast cancer: is insulin the missing link? Cancer Causes Control 7: 605–625CrossRefPubMedGoogle Scholar
  37. 37.
    Kaaks R, Lukanova A, Kurzer MA (2002) Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomark Prev 11: 1531–1543Google Scholar
  38. 38.
    Kapp KS, Stuecklschweiger GF, Kapp DS et al. (1997) Carcinoma of the cervix: analysis of complications after primary external beam radiation and IR-192 HDR brachytherapy. Radiother Oncol 42: 143CrossRefPubMedGoogle Scholar
  39. 39.
    Kopelman PG (2000) Obesity as a medical problem. Nature 404: 635–643PubMedGoogle Scholar
  40. 40.
    Kroenke C, Chen W, Rosner B et al. (2005) Weight, weight gain, and survival after breast cancer diagnosis. J Appl Physiol 23: 1370–1378Google Scholar
  41. 41.
    Lacey JV et al. (2003) Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer 98: 814–821CrossRefPubMedGoogle Scholar
  42. 42.
    Lew EA, Garfinkel L (1979) Variations in mortality by weight among 750,000 men and women. J Chronic Dis 32: 563–576CrossRefPubMedGoogle Scholar
  43. 43.
    Lindstek KD, Singh PN (1998) Body mass and 26y risk of mortality among men who never smoked: a re-analysis among men from the Adventist Mortality Study. Int J Obes Relat Metab Disord 22: 544–548CrossRefPubMedGoogle Scholar
  44. 44.
    Ma J, Pollak MN, Giovanucci E et al. (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91: 620–625CrossRefPubMedGoogle Scholar
  45. 45.
    Manson JE, Willett WC, Stampfer MJ et al. (1995) Body weight and mortality among women. N Engl J Med 333: 677–685CrossRefPubMedGoogle Scholar
  46. 46.
    Million Women Study Collaborators (2005) Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365: 1543–1551CrossRefPubMedGoogle Scholar
  47. 47.
    Mock V (2004) Evidence-based treatment for cancer-related fatigue. J Natl Cancer Inst Monogr 32: 112–118CrossRefPubMedGoogle Scholar
  48. 48.
    Modesitt SC, van Nagell JR (2005) The impact of obesity on the incidence and treatment of gynaecologic cancers: a review. ObstetGynecol Surv 60: 683–692CrossRefGoogle Scholar
  49. 49.
    Morimoto LM, White E, Chen Z et al. (2002) Obesity, body size, and risk of postmenopausal breast cancer: the Women’s Health Initiative (United States). Cancer Causes Control 13: 741–751CrossRefPubMedGoogle Scholar
  50. 50.
    Petrelli JM, Calle EE, Rodriguez C, Thun MJ (2002) Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of U.S. women. Cancer Causes Control 13: 325–332CrossRefPubMedGoogle Scholar
  51. 51.
    Powis G, Reece P, Ahmann DL et al. (1987) Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 20: 219CrossRefPubMedGoogle Scholar
  52. 52.
    Pugeat M et al. (1991) Pathophysiology of sex hormone binding globuline (SHGB): relation to insulin. J Steroid Biochem Mol Biol 40: 841–849CrossRefPubMedGoogle Scholar
  53. 53.
    Reeves M, Newcomb PA, Remington P et al. (1996) Body mass and breast cancer, relationship between method of detection and stage of disease. Cancer 77: 301–307CrossRefPubMedGoogle Scholar
  54. 54.
    Robert-Koch-Institut (Hrsg) (1999) Schwerpunktheft Bundes-Gesundheitssurvey 1998. Gesundheitswesen (Sonderheft 2) 61Google Scholar
  55. 55.
    Rock CL, Demark-Wahnefried W (2002) Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol 20: 3302–3316Google Scholar
  56. 56.
    Rodvold KA, Rushing DA, Tewksburry DA (1988) Doxorubicin clearance in the obese. J Clin Oncol 6: 1321Google Scholar
  57. 57.
    Schairer C et al. (2000) Menopausal estrogen end estrogen-progestin replacement therapy and breast cancer risk. JAMA 283: 485–491CrossRefPubMedGoogle Scholar
  58. 58.
    Silteri PK (1987) Adipose tissue as a source of hormones. Am J Clin Nutr 45: 277–282PubMedGoogle Scholar
  59. 59.
    Stephenson GD, Rose DP (2003) Breast cancer and obesity: an update. Nutr Cancer 45: 1–16CrossRefPubMedGoogle Scholar
  60. 60.
    Stoll BA (1999) Western nutrition and the insulin resistance syndrome: a link to breast cancer. Eur J Clin Nutr 53: 83–87CrossRefPubMedGoogle Scholar
  61. 61.
    Strumberg D, Boeing H, Scheulen ME et al. (2004) Ernährung, Lifestyle und Krebs: Wege zur Primärprävention. Dtsch Med Wochenschr 129: 1877–1882CrossRefPubMedGoogle Scholar
  62. 62.
    Swanson CA, Potischman N, Wilbanks GD et al.(1993) Relation of endometrial cancer risk to past and contemporary body size and body fat distribution. Cancer Epidemol Biomarkers Prev 2: 321Google Scholar
  63. 63.
    Tornberg SA, Carstensen JM (1994) Relationship between Quetelet’s index and cancer of breast and female genital tract in 47,000 women followed for 25 years. Br J Cancer 69: 358–361PubMedGoogle Scholar
  64. 64.
    Trentham-Dietz A et al. (1997) Body size and risk of breast cancer. Am J Epidemiol 145: 1011–1019PubMedGoogle Scholar
  65. 65.
    Wee C, McCarthy E, Davis R, Phillips R (2000) Screening for cervical and breast cancer: is obesity an unrecognised barrier to preventive care? Ann Intern Med 132: 697–704PubMedGoogle Scholar
  66. 66.
    WHO (1998) Preventing and managing the global epidemic. Report of a WHO consultation on obesity. WHO, GenevaGoogle Scholar
  67. 67.
    Wynder EL, Gori GB (1977) Contribution of the environment to cancer incidence: an epidemiologic exercise. J Natl Cancer Inst 58: 825–832PubMedGoogle Scholar
  68. 68.
    Yamauchi T, Kamon J, Waki H et al. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7: 941–946CrossRefPubMedGoogle Scholar
  69. 69.
    Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92: 1472–1489CrossRefPubMedGoogle Scholar
  70. 70.
    Yu H et al. (1999) Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91: 151–156CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2006

Authors and Affiliations

  1. 1.Klinik für Gynäkologie und GeburtshilfeGeorg-August-UniversitätGöttingenDeutschland

Personalised recommendations